Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats

Identifieur interne : 000706 ( PascalFrancis/Corpus ); précédent : 000705; suivant : 000707

MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats

Auteurs : Jessica M. Castellano ; Jody Batrynchuk ; Kristine Dolbeare ; Vaneeta Verma ; Amandeep Mann ; Kevin J. Skoblenick ; Rodney L. Johnson ; Ram K. Mishra

Source :

RBID : Pascal:07-0480619

Descripteurs français

English descriptors

Abstract

Two melanocyte-stimulating hormone release inhibiting factor-1 (MIF-1) also known as L-prolyl-L-leucyl-glycinamide (PLG) peptidomimetic analogs, 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]-amino] -3-(butyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (A) and 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]amino]-3-(benzyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (B), were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively. In the 6-OHDA model, both analogs were found to potentiate the contralateral rotational behavior induced by apomorphine dose-dependently and with approximately the same potency. Furthermore, each analog was able to significantly attenuate HP-induced VCMs with almost equal efficacy. The potency and efficacy of these analogs were significantly greater than their parent compound, PLG. These results suggest that both analogs can modulate dopaminergic activity in vivo, likely by the same mechanisms recruited by PLG previously reported.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0196-9781
A02 01      @0 PPTDD5
A03   1    @0 Peptides : (NY NY, 1980)
A05       @2 28
A06       @2 10
A08 01  1  ENG  @1 MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats
A11 01  1    @1 CASTELLANO (Jessica M.)
A11 02  1    @1 BATRYNCHUK (Jody)
A11 03  1    @1 DOLBEARE (Kristine)
A11 04  1    @1 VERMA (Vaneeta)
A11 05  1    @1 MANN (Amandeep)
A11 06  1    @1 SKOBLENICK (Kevin J.)
A11 07  1    @1 JOHNSON (Rodney L.)
A11 08  1    @1 MISHRA (Ram K.)
A14 01      @1 Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West @2 Hamilton, Ontario, L8N 3Z5 @3 CAN @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 8 aut.
A14 02      @1 Department of Medicinal Chemistry, University of Minnesota @2 Minneapolis, MN 55455 @3 USA @Z 3 aut. @Z 7 aut.
A20       @1 2009-2015
A21       @1 2007
A23 01      @0 ENG
A43 01      @1 INIST @2 19060 @5 354000149842240110
A44       @0 0000 @1 © 2007 INIST-CNRS. All rights reserved.
A45       @0 52 ref.
A47 01  1    @0 07-0480619
A60       @1 P
A61       @0 A
A64 01  1    @0 Peptides : (New York, NY. 1980)
A66 01      @0 USA
C01 01    ENG  @0 Two melanocyte-stimulating hormone release inhibiting factor-1 (MIF-1) also known as L-prolyl-L-leucyl-glycinamide (PLG) peptidomimetic analogs, 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]-amino] -3-(butyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (A) and 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]amino]-3-(benzyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (B), were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively. In the 6-OHDA model, both analogs were found to potentiate the contralateral rotational behavior induced by apomorphine dose-dependently and with approximately the same potency. Furthermore, each analog was able to significantly attenuate HP-induced VCMs with almost equal efficacy. The potency and efficacy of these analogs were significantly greater than their parent compound, PLG. These results suggest that both analogs can modulate dopaminergic activity in vivo, likely by the same mechanisms recruited by PLG previously reported.
C02 01  X    @0 002A28
C02 02  X    @0 002B17G
C02 03  X    @0 002B17A01
C02 04  X    @0 002B02B03
C03 01  X  FRE  @0 Analogue @5 01
C03 01  X  ENG  @0 Analog @5 01
C03 01  X  SPA  @0 Análogo @5 01
C03 02  X  FRE  @0 Halopéridol @2 NK @2 FR @5 02
C03 02  X  ENG  @0 Haloperidol @2 NK @2 FR @5 02
C03 02  X  SPA  @0 Haloperidol @2 NK @2 FR @5 02
C03 03  X  FRE  @0 Mastication @5 03
C03 03  X  ENG  @0 Chewing @5 03
C03 03  X  SPA  @0 Masticación @5 03
C03 04  X  FRE  @0 Apomorphine @2 NK @2 FR @5 04
C03 05  X  FRE  @0 Comportement @5 07
C03 05  X  ENG  @0 Behavior @5 07
C03 05  X  SPA  @0 Conducta @5 07
C03 06  X  FRE  @0 Oxidopamine @2 NK @2 FR @5 08
C03 06  X  ENG  @0 Oxidopamine @2 NK @2 FR @5 08
C03 06  X  SPA  @0 Oxidopamina @2 NK @2 FR @5 08
C03 07  X  FRE  @0 Parkinson maladie @5 09
C03 07  X  ENG  @0 Parkinson disease @5 09
C03 07  X  SPA  @0 Parkinson enfermedad @5 09
C03 08  X  FRE  @0 Animal @5 10
C03 08  X  ENG  @0 Animal @5 10
C03 08  X  SPA  @0 Animal @5 10
C03 09  X  FRE  @0 Contrôle moteur @5 11
C03 09  X  ENG  @0 Motor control @5 11
C03 09  X  SPA  @0 Control motor @5 11
C03 10  X  FRE  @0 Dyskinésie @5 12
C03 10  X  ENG  @0 Dyskinesia @5 12
C03 10  X  SPA  @0 Disquinesia @5 12
C03 11  X  FRE  @0 Lésion @5 13
C03 11  X  ENG  @0 Lesion @5 13
C03 11  X  SPA  @0 Lesión @5 13
C03 12  X  FRE  @0 Dopamine @2 NK @2 FR @5 14
C03 12  X  ENG  @0 Dopamine @2 NK @2 FR @5 14
C03 12  X  SPA  @0 Dopamina @2 NK @2 FR @5 14
C03 13  X  FRE  @0 MSH @5 15
C03 13  X  ENG  @0 Melanocyte stimulating hormone @5 15
C03 13  X  SPA  @0 MSH @5 15
C03 14  X  FRE  @0 Libération @5 16
C03 14  X  ENG  @0 Release @5 16
C03 14  X  SPA  @0 Liberación @5 16
C03 15  X  FRE  @0 Rat @5 69
C03 15  X  ENG  @0 Rat @5 69
C03 15  X  SPA  @0 Rata @5 69
C07 01  X  FRE  @0 Psychotrope @2 FX @5 20
C07 01  X  ENG  @0 Psychotropic @2 FX @5 20
C07 01  X  SPA  @0 Psicotropo @2 FX @5 20
C07 02  X  FRE  @0 Neuroleptique @5 21
C07 02  X  ENG  @0 Neuroleptic @5 21
C07 02  X  SPA  @0 Neuroléptico @5 21
C07 03  X  FRE  @0 Antagoniste dopamine @5 22
C07 03  X  ENG  @0 Dopamine antagonist @5 22
C07 03  X  SPA  @0 Antagonista dopamina @5 22
C07 04  X  FRE  @0 Butyrophénone dérivé @5 23
C07 04  X  ENG  @0 Butyrophenone derivatives @5 23
C07 04  X  SPA  @0 Butirofenona derivado @5 23
C07 05  X  FRE  @0 Récepteur dopaminergique D2 @5 24
C07 05  X  ENG  @0 D2 Dopamine receptor @5 24 @6 «D2» Dopamine receptor
C07 05  X  SPA  @0 Receptor dopaminérgico D2 @5 24
C07 06  X  FRE  @0 Agoniste @5 25
C07 06  X  ENG  @0 Agonist @5 25
C07 06  X  SPA  @0 Agonista @5 25
C07 07  X  FRE  @0 Récepteur dopaminergique D1 @5 26
C07 07  X  ENG  @0 D1 Dopamine receptor @5 26 @6 «D1» Dopamine receptor
C07 07  X  SPA  @0 Receptor dopaminérgico D1 @5 26
C07 08  X  FRE  @0 Stimulant dopaminergique @5 27
C07 08  X  ENG  @0 Dopamine agonist @5 27
C07 08  X  SPA  @0 Estimulante dopaminérgico @5 27
C07 09  X  FRE  @0 Récepteur adrénergique @5 28
C07 09  X  ENG  @0 Adrenergic receptor @5 28
C07 09  X  SPA  @0 Receptor adrenérgico @5 28
C07 10  X  FRE  @0 Sympathomimétique @5 29
C07 10  X  ENG  @0 Sympathomimetic @5 29
C07 10  X  SPA  @0 Simpaticomimético @5 29
C07 11  X  FRE  @0 Catécholamine @5 30
C07 11  X  ENG  @0 Catecholamine @5 30
C07 11  X  SPA  @0 Catecolamina @5 30
C07 12  X  FRE  @0 Neurotransmetteur @5 31
C07 12  X  ENG  @0 Neurotransmitter @5 31
C07 12  X  SPA  @0 Neurotransmisor @5 31
C07 13  X  FRE  @0 Hormone hypophysaire @5 38
C07 13  X  ENG  @0 Pituitary hormone @5 38
C07 13  X  SPA  @0 Hormona hipofisaria @5 38
C07 14  X  FRE  @0 Encéphale pathologie @5 39
C07 14  X  ENG  @0 Cerebral disorder @5 39
C07 14  X  SPA  @0 Encéfalo patología @5 39
C07 15  X  FRE  @0 Extrapyramidal syndrome @5 40
C07 15  X  ENG  @0 Extrapyramidal syndrome @5 40
C07 15  X  SPA  @0 Extrapiramidal síndrome @5 40
C07 16  X  FRE  @0 Maladie dégénérative @5 41
C07 16  X  ENG  @0 Degenerative disease @5 41
C07 16  X  SPA  @0 Enfermedad degenerativa @5 41
C07 17  X  FRE  @0 Système nerveux central pathologie @5 42
C07 17  X  ENG  @0 Central nervous system disease @5 42
C07 17  X  SPA  @0 Sistema nervosio central patología @5 42
C07 18  X  FRE  @0 Système nerveux pathologie @5 43
C07 18  X  ENG  @0 Nervous system diseases @5 43
C07 18  X  SPA  @0 Sistema nervioso patología @5 43
C07 19  X  FRE  @0 Mouvement involontaire @5 44
C07 19  X  ENG  @0 Involuntary movement @5 44
C07 19  X  SPA  @0 Movimiento involuntario @5 44
C07 20  X  FRE  @0 Trouble neurologique @5 45
C07 20  X  ENG  @0 Neurological disorder @5 45
C07 20  X  SPA  @0 Trastorno neurológico @5 45
C07 21  X  FRE  @0 Rodentia @2 NS
C07 21  X  ENG  @0 Rodentia @2 NS
C07 21  X  SPA  @0 Rodentia @2 NS
C07 22  X  FRE  @0 Mammalia @2 NS
C07 22  X  ENG  @0 Mammalia @2 NS
C07 22  X  SPA  @0 Mammalia @2 NS
C07 23  X  FRE  @0 Vertebrata @2 NS
C07 23  X  ENG  @0 Vertebrata @2 NS
C07 23  X  SPA  @0 Vertebrata @2 NS
N21       @1 316
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 07-0480619 INIST
ET : MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats
AU : CASTELLANO (Jessica M.); BATRYNCHUK (Jody); DOLBEARE (Kristine); VERMA (Vaneeta); MANN (Amandeep); SKOBLENICK (Kevin J.); JOHNSON (Rodney L.); MISHRA (Ram K.)
AF : Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West/Hamilton, Ontario, L8N 3Z5/Canada (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 8 aut.); Department of Medicinal Chemistry, University of Minnesota/Minneapolis, MN 55455/Etats-Unis (3 aut., 7 aut.)
DT : Publication en série; Niveau analytique
SO : Peptides : (New York, NY. 1980); ISSN 0196-9781; Coden PPTDD5; Etats-Unis; Da. 2007; Vol. 28; No. 10; Pp. 2009-2015; Bibl. 52 ref.
LA : Anglais
EA : Two melanocyte-stimulating hormone release inhibiting factor-1 (MIF-1) also known as L-prolyl-L-leucyl-glycinamide (PLG) peptidomimetic analogs, 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]-a mino] -3-(butyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (A) and 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]amino]-3-(benzyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (B), were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively. In the 6-OHDA model, both analogs were found to potentiate the contralateral rotational behavior induced by apomorphine dose-dependently and with approximately the same potency. Furthermore, each analog was able to significantly attenuate HP-induced VCMs with almost equal efficacy. The potency and efficacy of these analogs were significantly greater than their parent compound, PLG. These results suggest that both analogs can modulate dopaminergic activity in vivo, likely by the same mechanisms recruited by PLG previously reported.
CC : 002A28; 002B17G; 002B17A01; 002B02B03
FD : Analogue; Halopéridol; Mastication; Apomorphine; Comportement; Oxidopamine; Parkinson maladie; Animal; Contrôle moteur; Dyskinésie; Lésion; Dopamine; MSH; Libération; Rat
FG : Psychotrope; Neuroleptique; Antagoniste dopamine; Butyrophénone dérivé; Récepteur dopaminergique D2; Agoniste; Récepteur dopaminergique D1; Stimulant dopaminergique; Récepteur adrénergique; Sympathomimétique; Catécholamine; Neurotransmetteur; Hormone hypophysaire; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie; Mouvement involontaire; Trouble neurologique; Rodentia; Mammalia; Vertebrata
ED : Analog; Haloperidol; Chewing; Behavior; Oxidopamine; Parkinson disease; Animal; Motor control; Dyskinesia; Lesion; Dopamine; Melanocyte stimulating hormone; Release; Rat
EG : Psychotropic; Neuroleptic; Dopamine antagonist; Butyrophenone derivatives; D2 Dopamine receptor; Agonist; D1 Dopamine receptor; Dopamine agonist; Adrenergic receptor; Sympathomimetic; Catecholamine; Neurotransmitter; Pituitary hormone; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Involuntary movement; Neurological disorder; Rodentia; Mammalia; Vertebrata
SD : Análogo; Haloperidol; Masticación; Conducta; Oxidopamina; Parkinson enfermedad; Animal; Control motor; Disquinesia; Lesión; Dopamina; MSH; Liberación; Rata
LO : INIST-19060.354000149842240110
ID : 07-0480619

Links to Exploration step

Pascal:07-0480619

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats</title>
<author>
<name sortKey="Castellano, Jessica M" sort="Castellano, Jessica M" uniqKey="Castellano J" first="Jessica M." last="Castellano">Jessica M. Castellano</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Batrynchuk, Jody" sort="Batrynchuk, Jody" uniqKey="Batrynchuk J" first="Jody" last="Batrynchuk">Jody Batrynchuk</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Dolbeare, Kristine" sort="Dolbeare, Kristine" uniqKey="Dolbeare K" first="Kristine" last="Dolbeare">Kristine Dolbeare</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Medicinal Chemistry, University of Minnesota</s1>
<s2>Minneapolis, MN 55455</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Verma, Vaneeta" sort="Verma, Vaneeta" uniqKey="Verma V" first="Vaneeta" last="Verma">Vaneeta Verma</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mann, Amandeep" sort="Mann, Amandeep" uniqKey="Mann A" first="Amandeep" last="Mann">Amandeep Mann</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Skoblenick, Kevin J" sort="Skoblenick, Kevin J" uniqKey="Skoblenick K" first="Kevin J." last="Skoblenick">Kevin J. Skoblenick</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Johnson, Rodney L" sort="Johnson, Rodney L" uniqKey="Johnson R" first="Rodney L." last="Johnson">Rodney L. Johnson</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Medicinal Chemistry, University of Minnesota</s1>
<s2>Minneapolis, MN 55455</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mishra, Ram K" sort="Mishra, Ram K" uniqKey="Mishra R" first="Ram K." last="Mishra">Ram K. Mishra</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">07-0480619</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0480619 INIST</idno>
<idno type="RBID">Pascal:07-0480619</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000706</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats</title>
<author>
<name sortKey="Castellano, Jessica M" sort="Castellano, Jessica M" uniqKey="Castellano J" first="Jessica M." last="Castellano">Jessica M. Castellano</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Batrynchuk, Jody" sort="Batrynchuk, Jody" uniqKey="Batrynchuk J" first="Jody" last="Batrynchuk">Jody Batrynchuk</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Dolbeare, Kristine" sort="Dolbeare, Kristine" uniqKey="Dolbeare K" first="Kristine" last="Dolbeare">Kristine Dolbeare</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Medicinal Chemistry, University of Minnesota</s1>
<s2>Minneapolis, MN 55455</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Verma, Vaneeta" sort="Verma, Vaneeta" uniqKey="Verma V" first="Vaneeta" last="Verma">Vaneeta Verma</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mann, Amandeep" sort="Mann, Amandeep" uniqKey="Mann A" first="Amandeep" last="Mann">Amandeep Mann</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Skoblenick, Kevin J" sort="Skoblenick, Kevin J" uniqKey="Skoblenick K" first="Kevin J." last="Skoblenick">Kevin J. Skoblenick</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Johnson, Rodney L" sort="Johnson, Rodney L" uniqKey="Johnson R" first="Rodney L." last="Johnson">Rodney L. Johnson</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Medicinal Chemistry, University of Minnesota</s1>
<s2>Minneapolis, MN 55455</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Mishra, Ram K" sort="Mishra, Ram K" uniqKey="Mishra R" first="Ram K." last="Mishra">Ram K. Mishra</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Peptides : (New York, NY. 1980)</title>
<title level="j" type="abbreviated">Peptides : (NY NY, 1980)</title>
<idno type="ISSN">0196-9781</idno>
<imprint>
<date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Peptides : (New York, NY. 1980)</title>
<title level="j" type="abbreviated">Peptides : (NY NY, 1980)</title>
<idno type="ISSN">0196-9781</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Analog</term>
<term>Animal</term>
<term>Behavior</term>
<term>Chewing</term>
<term>Dopamine</term>
<term>Dyskinesia</term>
<term>Haloperidol</term>
<term>Lesion</term>
<term>Melanocyte stimulating hormone</term>
<term>Motor control</term>
<term>Oxidopamine</term>
<term>Parkinson disease</term>
<term>Rat</term>
<term>Release</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Analogue</term>
<term>Halopéridol</term>
<term>Mastication</term>
<term>Apomorphine</term>
<term>Comportement</term>
<term>Oxidopamine</term>
<term>Parkinson maladie</term>
<term>Animal</term>
<term>Contrôle moteur</term>
<term>Dyskinésie</term>
<term>Lésion</term>
<term>Dopamine</term>
<term>MSH</term>
<term>Libération</term>
<term>Rat</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Two melanocyte-stimulating hormone release inhibiting factor-1 (MIF-1) also known as L-prolyl-L-leucyl-glycinamide (PLG) peptidomimetic analogs, 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]-amino] -3-(butyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (A) and 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]amino]-3-(benzyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (B), were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively. In the 6-OHDA model, both analogs were found to potentiate the contralateral rotational behavior induced by apomorphine dose-dependently and with approximately the same potency. Furthermore, each analog was able to significantly attenuate HP-induced VCMs with almost equal efficacy. The potency and efficacy of these analogs were significantly greater than their parent compound, PLG. These results suggest that both analogs can modulate dopaminergic activity in vivo, likely by the same mechanisms recruited by PLG previously reported.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0196-9781</s0>
</fA01>
<fA02 i1="01">
<s0>PPTDD5</s0>
</fA02>
<fA03 i2="1">
<s0>Peptides : (NY NY, 1980)</s0>
</fA03>
<fA05>
<s2>28</s2>
</fA05>
<fA06>
<s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>CASTELLANO (Jessica M.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>BATRYNCHUK (Jody)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>DOLBEARE (Kristine)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>VERMA (Vaneeta)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>MANN (Amandeep)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>SKOBLENICK (Kevin J.)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>JOHNSON (Rodney L.)</s1>
</fA11>
<fA11 i1="08" i2="1">
<s1>MISHRA (Ram K.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West</s1>
<s2>Hamilton, Ontario, L8N 3Z5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Medicinal Chemistry, University of Minnesota</s1>
<s2>Minneapolis, MN 55455</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20>
<s1>2009-2015</s1>
</fA20>
<fA21>
<s1>2007</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>19060</s2>
<s5>354000149842240110</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>52 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>07-0480619</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Peptides : (New York, NY. 1980)</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Two melanocyte-stimulating hormone release inhibiting factor-1 (MIF-1) also known as L-prolyl-L-leucyl-glycinamide (PLG) peptidomimetic analogs, 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]-amino] -3-(butyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (A) and 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]amino]-3-(benzyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (B), were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively. In the 6-OHDA model, both analogs were found to potentiate the contralateral rotational behavior induced by apomorphine dose-dependently and with approximately the same potency. Furthermore, each analog was able to significantly attenuate HP-induced VCMs with almost equal efficacy. The potency and efficacy of these analogs were significantly greater than their parent compound, PLG. These results suggest that both analogs can modulate dopaminergic activity in vivo, likely by the same mechanisms recruited by PLG previously reported.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002A28</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X">
<s0>002B17A01</s0>
</fC02>
<fC02 i1="04" i2="X">
<s0>002B02B03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Analogue</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Analog</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Análogo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Halopéridol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Haloperidol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Haloperidol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Mastication</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Chewing</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Masticación</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Comportement</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Behavior</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Conducta</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Oxidopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Oxidopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Oxidopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Animal</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Animal</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Animal</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Contrôle moteur</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Motor control</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Control motor</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Dyskinésie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Dyskinesia</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Disquinesia</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Lésion</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Lesion</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Lesión</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>MSH</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Melanocyte stimulating hormone</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>MSH</s0>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Libération</s0>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Release</s0>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Liberación</s0>
<s5>16</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE">
<s0>Rat</s0>
<s5>69</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG">
<s0>Rat</s0>
<s5>69</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA">
<s0>Rata</s0>
<s5>69</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Psychotrope</s0>
<s2>FX</s2>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Psychotropic</s0>
<s2>FX</s2>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Psicotropo</s0>
<s2>FX</s2>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Neuroleptique</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Neuroleptic</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Neuroléptico</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Antagoniste dopamine</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Dopamine antagonist</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Antagonista dopamina</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Butyrophénone dérivé</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Butyrophenone derivatives</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Butirofenona derivado</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Récepteur dopaminergique D2</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>D2 Dopamine receptor</s0>
<s5>24</s5>
<s6>«D2» Dopamine receptor</s6>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Receptor dopaminérgico D2</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Agoniste</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Agonist</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Agonista</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Récepteur dopaminergique D1</s0>
<s5>26</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>D1 Dopamine receptor</s0>
<s5>26</s5>
<s6>«D1» Dopamine receptor</s6>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Receptor dopaminérgico D1</s0>
<s5>26</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Stimulant dopaminergique</s0>
<s5>27</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Dopamine agonist</s0>
<s5>27</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Estimulante dopaminérgico</s0>
<s5>27</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Récepteur adrénergique</s0>
<s5>28</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Adrenergic receptor</s0>
<s5>28</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Receptor adrenérgico</s0>
<s5>28</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Sympathomimétique</s0>
<s5>29</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Sympathomimetic</s0>
<s5>29</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Simpaticomimético</s0>
<s5>29</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE">
<s0>Catécholamine</s0>
<s5>30</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG">
<s0>Catecholamine</s0>
<s5>30</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA">
<s0>Catecolamina</s0>
<s5>30</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE">
<s0>Neurotransmetteur</s0>
<s5>31</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG">
<s0>Neurotransmitter</s0>
<s5>31</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA">
<s0>Neurotransmisor</s0>
<s5>31</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE">
<s0>Hormone hypophysaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="13" i2="X" l="ENG">
<s0>Pituitary hormone</s0>
<s5>38</s5>
</fC07>
<fC07 i1="13" i2="X" l="SPA">
<s0>Hormona hipofisaria</s0>
<s5>38</s5>
</fC07>
<fC07 i1="14" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="14" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="14" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="15" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="15" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="15" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="16" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="16" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="16" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="17" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="17" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="17" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="18" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>43</s5>
</fC07>
<fC07 i1="18" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>43</s5>
</fC07>
<fC07 i1="18" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="19" i2="X" l="FRE">
<s0>Mouvement involontaire</s0>
<s5>44</s5>
</fC07>
<fC07 i1="19" i2="X" l="ENG">
<s0>Involuntary movement</s0>
<s5>44</s5>
</fC07>
<fC07 i1="19" i2="X" l="SPA">
<s0>Movimiento involuntario</s0>
<s5>44</s5>
</fC07>
<fC07 i1="20" i2="X" l="FRE">
<s0>Trouble neurologique</s0>
<s5>45</s5>
</fC07>
<fC07 i1="20" i2="X" l="ENG">
<s0>Neurological disorder</s0>
<s5>45</s5>
</fC07>
<fC07 i1="20" i2="X" l="SPA">
<s0>Trastorno neurológico</s0>
<s5>45</s5>
</fC07>
<fC07 i1="21" i2="X" l="FRE">
<s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="21" i2="X" l="ENG">
<s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="21" i2="X" l="SPA">
<s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="22" i2="X" l="FRE">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="22" i2="X" l="ENG">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="22" i2="X" l="SPA">
<s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="23" i2="X" l="FRE">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="23" i2="X" l="ENG">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="23" i2="X" l="SPA">
<s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21>
<s1>316</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 07-0480619 INIST</NO>
<ET>MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats</ET>
<AU>CASTELLANO (Jessica M.); BATRYNCHUK (Jody); DOLBEARE (Kristine); VERMA (Vaneeta); MANN (Amandeep); SKOBLENICK (Kevin J.); JOHNSON (Rodney L.); MISHRA (Ram K.)</AU>
<AF>Department of Psychiatry and Behavioral Neurosciences, McMaster University, 1200 Main Street West/Hamilton, Ontario, L8N 3Z5/Canada (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 8 aut.); Department of Medicinal Chemistry, University of Minnesota/Minneapolis, MN 55455/Etats-Unis (3 aut., 7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Peptides : (New York, NY. 1980); ISSN 0196-9781; Coden PPTDD5; Etats-Unis; Da. 2007; Vol. 28; No. 10; Pp. 2009-2015; Bibl. 52 ref.</SO>
<LA>Anglais</LA>
<EA>Two melanocyte-stimulating hormone release inhibiting factor-1 (MIF-1) also known as L-prolyl-L-leucyl-glycinamide (PLG) peptidomimetic analogs, 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]-a mino] -3-(butyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (A) and 3(R)-[[[2(S)-pyrrolidinyl]carbonyl]amino]-3-(benzyl)-2-oxo-1-pyrrolidineacetamide trifluoroacetate (B), were evaluated for their ability to modulate dopaminergic activity by measuring apomorphine-induced rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats, and haloperidol (HP)-induced vacuous chewing movements (VCMs) in rats; animal models of Parkinson's disease (PD) and human tardive dyskinesia (TD), respectively. In the 6-OHDA model, both analogs were found to potentiate the contralateral rotational behavior induced by apomorphine dose-dependently and with approximately the same potency. Furthermore, each analog was able to significantly attenuate HP-induced VCMs with almost equal efficacy. The potency and efficacy of these analogs were significantly greater than their parent compound, PLG. These results suggest that both analogs can modulate dopaminergic activity in vivo, likely by the same mechanisms recruited by PLG previously reported.</EA>
<CC>002A28; 002B17G; 002B17A01; 002B02B03</CC>
<FD>Analogue; Halopéridol; Mastication; Apomorphine; Comportement; Oxidopamine; Parkinson maladie; Animal; Contrôle moteur; Dyskinésie; Lésion; Dopamine; MSH; Libération; Rat</FD>
<FG>Psychotrope; Neuroleptique; Antagoniste dopamine; Butyrophénone dérivé; Récepteur dopaminergique D2; Agoniste; Récepteur dopaminergique D1; Stimulant dopaminergique; Récepteur adrénergique; Sympathomimétique; Catécholamine; Neurotransmetteur; Hormone hypophysaire; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie; Mouvement involontaire; Trouble neurologique; Rodentia; Mammalia; Vertebrata</FG>
<ED>Analog; Haloperidol; Chewing; Behavior; Oxidopamine; Parkinson disease; Animal; Motor control; Dyskinesia; Lesion; Dopamine; Melanocyte stimulating hormone; Release; Rat</ED>
<EG>Psychotropic; Neuroleptic; Dopamine antagonist; Butyrophenone derivatives; D2 Dopamine receptor; Agonist; D1 Dopamine receptor; Dopamine agonist; Adrenergic receptor; Sympathomimetic; Catecholamine; Neurotransmitter; Pituitary hormone; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Involuntary movement; Neurological disorder; Rodentia; Mammalia; Vertebrata</EG>
<SD>Análogo; Haloperidol; Masticación; Conducta; Oxidopamina; Parkinson enfermedad; Animal; Control motor; Disquinesia; Lesión; Dopamina; MSH; Liberación; Rata</SD>
<LO>INIST-19060.354000149842240110</LO>
<ID>07-0480619</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000706 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000706 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0480619
   |texte=   MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022